TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
NeuroOne Medical Technologies ( (NMTC) ) has issued an announcement.
On November 4, 2025, NeuroOne Medical Technologies received a 180-day extension from Nasdaq to comply with the minimum bid price requirement of $1.00 per share for its common stock to remain listed. The extension allows the company until May 4, 2026, to address the compliance issue, with no immediate impact on its current Nasdaq listing. Failure to meet the requirement by the deadline could lead to delisting, although the company plans to monitor and address the issue within the given timeframe.
The most recent analyst rating on (NMTC) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on NeuroOne Medical Technologies stock, see the NMTC Stock Forecast page.
Spark’s Take on NMTC Stock
According to Spark, TipRanks’ AI Analyst, NMTC is a Neutral.
NeuroOne Medical Technologies’ overall stock score is driven by strong revenue growth and positive earnings call sentiment. However, the company’s ongoing profitability challenges and negative valuation metrics weigh heavily on the score. Technical indicators suggest a bearish trend, but potential for a rebound exists as the stock approaches oversold levels.
To see Spark’s full report on NMTC stock, click here.
More about NeuroOne Medical Technologies
NeuroOne Medical Technologies Corporation operates in the medical technology industry, focusing on developing and commercializing minimally invasive solutions for neurological conditions. The company’s primary products include electrode technology for brain-related disorders, targeting markets such as epilepsy, Parkinson’s disease, and chronic pain.
Average Trading Volume: 399,660
Technical Sentiment Signal: Strong Sell
Current Market Cap: $36.14M
See more data about NMTC stock on TipRanks’ Stock Analysis page.